November 10, 2014: BioAegis Therapeutics Seeks Advice from MHRA and MPA in Anticipation of European Phase 2 Clinical Studies

Company To Sponsor Phase 2 Trials in Community-Acquired Pneumonia in Europe

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 10, 2014) BioAegis Therapeutics reports that its clinical program was well-­received by two EU regulatory authorities, the MHRA in the United Kingdom and the MPA in Sweden. After completion of required preparatory work the company intends to file a Clinical Trial Application (CTA) and initiate a phase 2a trial in severe community-acquired pneumonia in the EU.